{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not reached due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"22.2","upperLimit":"NA","value":"53.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Defined as teh time from first dose date to the date of death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"OG000","title":"Experimental: Nab-Sirolimus"}],"paramType":"MEDIAN","populationDescription":"Treated Patient Population","reportingStatus":"POSTED","timeFrame":"From start of treatment to date of death (of any cause), through study completion (up to 72 months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}